INDIGO Announces upcyte® Product Agreement

Share Article

Agreement aims to reduce high rates of drug-induced liver damage. Meets increasing demand for predictive liver toxicity models

Hepatoxicity remains a major reason for drug withdrawal from pharmaceutical development and clinical use. These cells offer a very attractive model to predict liver damage caused by drugs and chemicals of environmental concern.

INDIGO Biosciences, the recognized industry leader in Nuclear Receptor research, and upcyte® technologies GmbH announced completion of a distribution partnership. This agreement meets the demand for predictive liver toxicity models, necessary due to the high attrition rate of drugs found to cause liver damage following entry into the market. upcyte® technologies GmbH, based in Hamburg-Eppendorf, Germany, is a life sciences company specializing in controlled, scalable propagation and standardization of human primary cell products. The upcyte® Hepatocytes will be used as a part of INDIGO's in vitro toxicology platform.

upcyte® technology allows controlled proliferation beyond the typical life span of primary cells without either immortalization or loss of differentiation properties. Utilizing upcyte® human liver cells, INDIGO has completed break-through developments in optimization, decreasing donor-to-donor variability while maintaining many Phase I and Phase II enzyme activities, making these cells more comparable to primary hepatocytes. The virtually unlimited availability of differentiated cells and their long viability period gives upcyte® hepatocytes an advantage over other commonly used cells.

Using this unique platform, INDIGO's services lab can examine your compound's potential to cause liver toxicity through metabolic activation or by induction of drug metabolism enzymes. upcyte® hepatocytes contain equivalent activity of several cytochrome P450s when compared to human hepatocytes, making the examination of metabolism-dependent toxicity biologically relevant. As with primary human hepatocytes, the induction response is donor-dependent; therefore, upcyte® hepatocytes offer a panel of different donors with a range of induction responses, allowing for greater end-stage predictability. In addition, INDIGO is able to strengthen and quantify changes in expression of target genes regulated by PXR, CAR, AhR, LXRs, LRH-1, PPARs, and Nrf2.

"There is an increasing demand to develop more predictive models for liver toxicity," says Dr. Jack Vanden Heuvel, INDIGO's Chief Scientific Officer. "Hepatotxicity remains a major reason for drug withdrawal from pharmaceutical development and clinical use. These cells offer a very attractive model to predict hepatotoxicity caused by drugs and chemicals of environmental concern."

About INDIGO Biosciences, Inc.
INDIGO Biosciences was founded in 2005 in State College, Pennsylvania, and has established itself as an industry-leading provider of both products and services focused on nuclear receptors. INDIGO offers both screening services and assay kits for the pharmaceutical, biotechnology, agri-business, and nutriceutical industries, as well as government research agencies and academic researchers.

For more information on INDIGO's products and services, please visit

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Tonya Daher
INDIGO Biosciences, Inc.
+1 (814) 234-1919 Ext: 133
Email >
Follow >
INDIGO Biosciences, INC

Visit website